Sonia Perales

Dr. Sonia Perales


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Pancreas
Verified
Journal Article
Closed access
CTCarolina Torres
Carolina Torres
SPSonia Perales
Sonia Perales
MAMaría José Alejandre
María José Alejandre
JIJosé Iglesias
José Iglesias
RPRogelio Jesús Palomio-Morales
Rogelio Jesús Palomio-Morales
ALAna Linares
Ana Linares
Pancreatic ductal adenocarcinoma is a deadly disease because of late diagnosis and chemoresistance. We aimed to find a panel of serum cytokines representing diagnostic and predictive biomarkers for pancreatic cancer. A cytokine antibody array was performed to simultaneously identify 507 cytokines in sera of patients with pancreatic cancer and healthy controls. The nonparametric Mann-Whitney U test was used to pairwise compare the controls, the pretreated patients, and the posttreated patients. Fold changes greater than or equal to 1.5 or less than or equal to 1/1.5 were considered significant. Receiver operating characteristic curves were used to assess the performance of the model. A leave-one-out cross-validation was used for estimating prediction error. Comparing the sera of pretreated patients against the control samples, the cytokines fibroblast growth factor 10 (FGF-10/keratinocyte growth factor-2 (KGF-2), chemokine (C-X-C motif) ligand 11 interferon inducible T cell alpha chemokine (I-TAC)/chemokine [C-X-C motif] ligand 11 (CXCL11), oncostatin M (OSM), osteoactivin/glycoprotein nonmetastatic melanoma protein B, and stem cell factor (SCF) were found significantly overexpressed. Besides, the cytokines CD30 ligand/tumor necrosis factor superfamily, member 8 (TNFSF8), chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF were differentially expressed in response to treatment. We propose a role for FGF-10/KGF-2, I-TAC/CXCL11, OSM, osteoactivin/glycoprotein nonmetastatic melanoma protein B, and SCF as novel diagnostic biomarkers. CD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.

23 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ISIris Simón Sáez
Iris Simón Sáez
SPSonia Perales
Sonia Perales
LMLaura Casado Medina
Laura Casado Medina
ARAlba Rodríguez-Martínez
Alba Rodríguez-Martínez
MNMaria del Carmen Garrido Navas
Maria del Carmen Garrido Navas
PRPedro Jose Real
Pedro Jose Real
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status (CRPC) is commonly developed. The expression of androgen receptor (AR) alternative splicing isoforms (AR-V7 and AR-V9) has been associated to CRPC. However, resistance mechanisms to novel NHAs are not yet well understood. Androgen-dependent PCa cell lines were used to generate resistant models to ADT only or in combination with Abiraterone and/or Enzalutamide (concomitant models). Functional and genetic analyses were performed for each resistance model by real-time cell monitoring assays, flow cytometry and RT-qPCR. In androgen-dependent PCa cells, the administration of Abiraterone and/or Enzalutamide as first-line treatment involved a critical inhibition of AR activity associated with a significant cell growth inhibition. Genetic analyses on ADT-resistant PCa cell lines showed that the CRPC phenotype was accompanied by overexpression of AR full-length and AR target genes, but not necessarily AR-V7 and/or AR-V9 isoforms. These ADT resistant cell lines showed higher proliferation rates, migration and invasion abilities. Importantly, ADT resistance induced cross-resistance to Abiraterone and/or Enzalutamide. Similarly, concomitant models possessed an elevated expression of AR full-length and proliferation rates and acquired cross-resistance to its alternative NHA as second-line treatment.

29 July 2014 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
OCOctavio Caba
Octavio Caba
JPJose Prados
Jose Prados
RORaul Ortiz
Raul Ortiz
CJCristina Jiménez-Luna
Cristina Jiménez-Luna
CMConsolación Melguizo
Consolación Melguizo
AAAntonia Aránega
Antonia Aránega

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CTCarolina Torres
Carolina Torres
ALAna Linares
Ana Linares
MAMaria José Alejandre
Maria José Alejandre
RPRogelio Jesús Palomio-Morales
Rogelio Jesús Palomio-Morales
OCOctavio Caba
Octavio Caba
SPSonia Perales
Sonia Perales
The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although gemcitabine is the standard used chemotherapy for this disease, clinical outcomes do not reflect significant improvements, not even when combined with adjuvant treatments. There is an urgent need for prognosis markers to be found. The aim of this study was to analyze the potential value of serum cytokines to find a profile that can predict the clinical outcome in patients with pancreatic cancer and to establish a practical prognosis index that significantly predicts patients’ outcomes. We have conducted an extensive analysis of serum prognosis biomarkers using an antibody array comprising 507 human cytokines. Overall survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox’s proportional hazard models were used to analyze prognosis factors. To determine the extent that survival could be predicted based on this index, we used the leave-one-out cross-validation model. The multivariate model showed a better performance and it could represent a novel panel of serum cytokines that correlates to poor prognosis in pancreatic cancer. B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer and these cytokines could represent novel therapeutic targets for this disease.

1 September 2006 in Cardiovascular & Hematological Disorders-Drug Targets
Verified
Journal Article
Closed access
PDF file
ALA. Linares
A. Linares
SPSonia Perales
Sonia Perales
RPRogelio Jesús Palomio-Morales
Rogelio Jesús Palomio-Morales
MCM. Castillo
M. Castillo
MAM. J. Alejandre
M. J. Alejandre
Contractile-state smooth muscle cells (SMC), the only cell type in the arterial media, undergoes migration to the intima, proliferation, and abundant extracellular matrix production during the early stages of atherosclerosis. This involves the ingestion of low-density lipoprotein (LDL) and modified or oxidised LDL by macrophages together with SMC by several pathways including a scavenger pathway leading to accumulation of cholesterol esters and formation of foam cells. High-plasma cholesterol levels constitute a major causative risk for atherosclerosis. The membrane-bound transcription factor called sterol regulatory element binding protein (SREBP) activates gene-encoding enzymes of cholesterol and fatty acid biosynthesis. The SREBP expression, in response to diet, shows that are involved in both lipogenesis and cholesterol homeostasis, moreover SREBPs are regulated directly by cholesterol. Animal models were used in trials of atherosclerosis, and cholesterol feeding has been described elsewhere as producing atherosclerotic lesions. We have examined the morphological, molecular and proliferative change in arterial SMC mimicking such a cholesterol diet, this transformed SMC is a good model to study the alterations of the differentiated state of SMC, and the transformation into foam cell, caused by cholesterol-rich diet. Despite the complexity of the interactions in atherosclerosis, there are many opportunities to affect the homeostatic balance of the artery wall at SMC levels. We have considered here some of the possible targets for intervention with promising strategies for the nutritional control of the genes, and, in a general way, the possibilities for modulating the expression of genes influencing atherosclerosis.

1 January 2009 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SPSonia Perales
Sonia Perales
MAM José Alejandre
M José Alejandre
RPRogelio Jesús Palomio-Morales
Rogelio Jesús Palomio-Morales
CTCarolina Torres
Carolina Torres
JIJose Iglesias
Jose Iglesias
ALAna Linares
Ana Linares
Smooth muscle cells (SMCs) undergo changes related to proliferation and apoptosis in the physiological remodeling of vessels and in diseases such as atherosclerosis and restenosis. Recent studies also have demonstrated the vascular cell proliferation and programmed cell death contribute to changes in vascular architecture in normal development and in disease. The present study was designed to investigate the apoptotic pathways induced by 25‐hydroxycholesterol in SMCs cultures, using an in vivo/in vitro cell model in which SMCs were isolated and culture from chicken exposed to an atherogenic cholesterol‐rich diet (SMC‐Ch) and/or an antiatherogenic fish oil‐rich diet (SMC‐Ch‐FO). Cells were exposed in vitro to 25‐hydroxycholesterol to study levels of apoptosis and apoptotic proteins Bcl‐2, Bcl‐XL and Bax and the expression of bcl‐2 and bcl‐xL, genes. The quantitative real‐time reverse transcriptase‐polymerase chain reaction and the Immunoblotting western blot analysis showed that 25‐hydroxycholesterol produces apoptosis in SMCs, mediated by a high increase in Bax protein and Bax gene expression. These changes were more marked in SMC‐Ch than in SMC‐Ch‐FO, indicating that dietary cholesterol produces changes in SMCs that make them more susceptible to 25‐hydroxycholesterol‐mediated apoptosis. Our results suggest that the replacement of a cholesterol‐rich diet with a fish oil‐rich diet produces some reversal of cholesterol‐induced changes in the apoptotic pathways induced by 25‐hydroxycholesterol in SMCs cultures, making SMCs more resistant to apoptosis.